Ecadotril
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Ecadotril
- Molecular weight
- 385.49
- Structure (SMILES)
- CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1
- bay y 7432
- BAY Y 7432
- BAY-Y-7432
- bp 1 02
- BP 1.02
- bp 102
- BP-1.02
- bp102
- BP102
- BP102 (B7-H3 CAR-T)
- bp102 b7 h3 car t
- bp102 injection
- BP102 Injection
- bp102 paclitaxel carboplatin
- ecadotril
- Ecadotril
- ecadotril [INN]
- ECADOTRIL [USAN]
- ecadotril inn
- ecadotril usan
- ecadotrilo
- Ecadotrilo
- fh 006 shr 1316 bp102
- fh 006 shr 1316 bp102 cisplatin carboplatin
- glycine n 2 acetylthio methyl 1 oxo 3 phenylpropyl phenylmethyl ester s
And 18 more, listed on the interactive page.
- CAS registry numbers
- 112573-73-6
- ChEMBL ID
- CHEMBL1516410
- InChIKey
- ODUOJXZPIYUATO-LJQANCHMSA-N
- PubChem compound IDs
- 60561
- FDA ingredient codes (UNII)
- 6XSR933SRK
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tril
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 2
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 72.47
- Calculated partition coefficient (ALogP)
- 2.98
- Calculated partition coefficient (XLogP)
- 3.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 9
- Heavy atoms
- 27
- Molecular formula
- C21H23NO4S
- Monoisotopic mass
- 385.13477939
- Natural product
- Yes
- Recorded assays
- 902
- Active assays
- 34
- Confirmatory
- Other
- Screening
- Summary
- Antidiarrheals
Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition.
- Protease Inhibitors
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Related records
Trials (14)
- A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
- A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
- A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
- A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
- An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)
- SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
- SHR-1701 Combined with SHR2554 and BP102 for MCRC
- SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
- Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
- To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC
- Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
In development for (4)
- Breast cancer Phase 2
- Colorectal cancer Phase 2
- Lung cancer Phase 2
- Non-small cell lung carcinoma Phase 3